Table of Contents

• Trial overview
• Who is studied
• What is measured
• Trial phases and status
• Treatment comparisons
• What these studies may mean for patients

Trial overview

The trial data show two authorised interventional studies that include Ziprasidone among the treatments being examined.^[1][2] One study is a Phase 4 trial in people with a recent diagnosis of schizophrenia and schizophrenia spectrum disorders, and the other is a Phase 3 trial in people with schizophrenia, schizoaffective disorder, or schizophreniform disorder.^[1][2]

Who is studied

The Phase 4 study includes people with a recent diagnosis of schizophrenia, which means the illness was identified not long before the trial.^[1] The Phase 3 study includes people who had a first-time treatment failure on their first-line treatment, so it focuses on patients whose first treatment did not work well enough.^[2]

The conditions listed across the trials are schizophrenia, schizophrenia spectrum disorders, schizoaffective disorder, and schizophreniform disorder.^[1][2] These are related mental health conditions that can involve psychosis, which means a person may have trouble telling what is real and what is not.^[2]

What is measured

One main outcome is cognitive functioning, which means thinking skills such as memory, attention, and problem-solving.^[1] This is measured with the BACS App score, and the study looks at change from baseline, meaning the difference from the starting point to later visits.^[1]

The other main outcome is symptom severity, measured with the PANSS total score, which is a standard scale used to track symptoms of psychosis.^[2] The Phase 3 study compares the mean change from baseline to six weeks between early-intensified pharmacological treatment and treatment as usual.^[2]

The Phase 4 study also lists time points at baseline, week 24, week 26, and week 50, showing that it follows participants over time to see whether scores change.^[1]

Trial phases and status

Both studies are marked Authorised, which means they have approval to be conducted.^[1][2] The first study is Phase 4 and has 37 participants, while the second is Phase 3 and has 418 participants.^[1][2]

Phase 3 studies usually compare treatments in larger groups to understand how well they work, while Phase 4 studies look at an already authorised treatment in a new or specific setting.^[1][2]

Treatment comparisons

In these studies, Ziprasidone is one of several drugs listed, not the only treatment being tested.^[1][2] The first trial lists many oral drugs, including quetiapine, risperidone, olanzapine, aripiprazole, and others, alongside Ziprasidone.^[1] The second trial also lists several oral and one intramuscular treatment option, including haloperidol, clozapine, lurasidone, and others, alongside Ziprasidone.^[2]

This means the research is looking at treatment strategies in real clinical settings, where several antipsychotic medicines may be considered.^[1][2] The trial summaries do not give detailed results, so the main focus is on study design and what the researchers want to measure.^[1][2]

What these studies may mean for patients

For patients, these trials show that Ziprasidone is being studied in people with early or treatment-resistant forms of schizophrenia-related illness.^[1][2] The studies are not just looking at symptom control, but also at thinking skills and how treatment changes over time.^[1] Because the trials include different patient groups, the findings may help researchers understand where Ziprasidone fits within broader treatment plans for psychotic disorders.^[1][2]